Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pevonedistat plus niraparib in recurrent ovarian cancer
jRCT2031210181Phase 2Suspended
- Sponsor
- Takeda
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pevonedistat and niraparib in Ovarian Epithelial Adenocarcinoma, sponsored by Takeda. Primary endpoint: Overall Response Rate. Started Sep 2021; status: suspended.
02
Drugs
pevonedistatniraparib
03
Conditions
Ovarian Epithelial Adenocarcinoma
Beyond the preview
Go deeper on jRCT2031210181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210181.